+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 130Years
All Genders
ID07596784

Open-label Study Evaluating Ravulizumab Infusion in Chinese Adults with Generalized Myasthenia Gravis

Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-10-21

20

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of ravulizumab in Chinese adults diagnosed with generalized Myasthenia Gravis gMG who test positive for acetylcholine receptor antibodies. This Phase 3 trial aims to assess how well the drug works, its safety, how the body processes it, its biological effects, and the immune response it may cause. Participants will receive ravulizumab through intravenous infusion for up to 26 weeks. The study is open-label and single-arm, meaning all participants receive the same treatment to evaluate its effects without a comparison group. The treatment period lasts up to 26 weeks, during which the drug is administered and monitored. Throughout the study, participants will undergo assessments including evaluations of daily living activities affected by myasthenia gravis, muscle strength, fatigue, and quality of life at the start and at 26 weeks. Blood samples will be collected to measure drug levels, immune responses, and safety markers up to week 34. The study tracks adverse events and other safety concerns while participants remain in the trial for approximately six months.

CONDITIONS

Brief Title

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Research Team

A

Alexion Pharmaceuticals, Inc. (Sponsor)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here